Edinburgh Research Explorer

Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis

Research output: Contribution to journalArticlepeer-review

Related Edinburgh Organisations

Open Access permissions



Original languageEnglish
JournalJournal of Medicinal Chemistry
Early online date28 Mar 2017
Publication statusPublished - 27 Apr 2017


Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments for neurodegenerative conditions and particularly for Huntington's disease. However, the inhibitors reported to date have insufficient aqueous solubility relative to their cellular potency to be compatible with the intravenous (iv) dosing route required in AP. We have identified and optimized a novel series of high affinity KMO inhibitors with favorable physicochemical properties. The leading example is exquisitely selective, has low clearance in two species, prevents lung and kidney damage in a rat model of acute pancreatitis, and is progressing into preclinical development.

    Research areas

  • Journal Article

Download statistics

No data available

ID: 35514873